Neither Auvelity nor Rexulti is automatically the better treatment for dementia agitation. Both are FDA-approved for agitation associated with dementia due to Alzheimer’s disease, but they carry different risks. Auvelity is a non-antipsychotic antidepressant combination that avoids the antipsychotic class warning about increased mortality in older adults with dementia-related psychosis. Rexulti is an atypical antipsychotic with that boxed warning, as well as risks involving stroke, movement disorders, metabolism, blood pressure, swallowing, and falls.
The safer choice depends on the person’s medical history, medications, symptoms, and treatment goals. For example, Auvelity may be unsuitable for someone with a seizure disorder or uncontrolled hypertension, while Rexulti may be especially concerning for someone with prior strokes, recurrent fainting, diabetes, or emerging involuntary movements. Neither drug is approved as an as-needed rescue medication, and neither should replace an evaluation for pain, infection, constipation, medication toxicity, or an overstimulating environment. Agitation may include pacing, repetitive movements, shouting, resistance to care, or physical aggression. Medication becomes more reasonable when these behaviors cause substantial distress, disrupt essential care, or threaten safety after reversible causes and non-drug approaches have been addressed.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Is Auvelity or Rexulti Better for Dementia Agitation?
- Auvelity Antidepressant Risks in Alzheimer’s Agitation
- Rexulti Antipsychotic Risks in Older Adults With Dementia
- How Clinicians Choose and Monitor Auvelity or Rexulti
- Common Problems During Treatment and Reassessment
- Non-Drug Care Alongside Medication
- Questions Families Should Bring to the Prescriber
- Frequently Asked Questions
Is Auvelity or Rexulti Better for Dementia Agitation?
auvelity combines dextromethorphan with bupropion. Dextromethorphan affects NMDA and sigma-1 signaling, while bupropion inhibits the CYP2D6 enzyme and increases dextromethorphan exposure. Rexulti contains brexpiprazole, an atypical antipsychotic that acts on dopamine and serotonin receptors. Both have a specific FDA indication for agitation associated with dementia due to Alzheimer’s disease, but this approval does not automatically extend to vascular dementia, Lewy body dementia, frontotemporal dementia, or unspecified dementia. There has not been a direct head-to-head trial establishing that one drug works better or is safer.
Auvelity’s pivotal short-term trial lasted five weeks, while Rexulti’s supporting fixed-dose trials lasted 12 weeks and used different populations and study designs. Comparing raw improvement scores across those studies would therefore be misleading. The FDA labels report that each drug improved caregiver-observed agitation measures compared with placebo in its own trials, not that either defeated the other. Symptom pattern can influence the discussion without determining the answer. A resident who persistently paces and strikes staff during personal care may be considered for either drug after pain and environmental triggers are addressed. If the same resident also has hallucinations or delusions that contribute to aggression, a clinician may place greater value on Rexulti’s antipsychotic properties, while still accounting for its more serious class warnings.
Auvelity Antidepressant Risks in Alzheimer’s Agitation
Auvelity does not carry the antipsychotic boxed warning for increased mortality in older adults with dementia-related psychosis. It does carry an antidepressant boxed warning about increased suicidal thoughts and behaviors in adolescents and young adults, although the typical Alzheimer’s population is much older. Risks more directly relevant to older adults include dizziness, falls, seizures, elevated blood pressure, serotonin syndrome, confusion, psychotic reactions, mania or hypomania, angle-closure glaucoma, and low blood sodium. In the Alzheimer’s agitation trial, dizziness occurred in 9% of Auvelity recipients and 3% of placebo recipients, prompting the label to recommend fall precautions. FDA prescribing information for Auvelity The bupropion component makes a careful seizure review essential. Auvelity is contraindicated in people with a seizure disorder, a current or previous diagnosis of bulimia or anorexia nervosa, or abrupt withdrawal from alcohol, benzodiazepines, barbiturates, or antiseizure medicines.
Severe stroke, low sodium, low blood sugar, low oxygen, serious head injury, and drugs that lower the seizure threshold can add risk. If a seizure occurs during treatment, the prescribing information says Auvelity should be discontinued and not restarted. Medication interactions are a significant limitation. Other products containing dextromethorphan—including some nonprescription cough medicines—can increase neuropsychiatric or serotonin-related toxicity. Combining Auvelity with an SSRI or tricyclic antidepressant may contribute to serotonin syndrome, with possible agitation, fever, sweating, tremor, muscle jerks, overactive reflexes, and unstable blood pressure. Monoamine oxidase inhibitors are contraindicated within specified separation periods, and bupropion’s CYP2D6 inhibition can alter exposure to other medications.
Rexulti Antipsychotic Risks in Older Adults With Dementia
Rexulti carries a boxed warning that older adults with dementia-related psychosis treated with antipsychotic drugs have an increased risk of death. The class evidence cited in its label found mortality about 1.6 to 1.7 times higher with antipsychotics than with placebo during typical 10-week trials, with deaths often cardiovascular or infectious. Rexulti’s approval applies to agitation associated with Alzheimer’s dementia; it is not approved simply to treat dementia-related psychosis without that qualifying agitation. FDA prescribing information for Rexulti Additional warnings include cerebrovascular events such as stroke, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, low white blood cell counts, orthostatic hypotension, falls, seizures, impaired temperature regulation, swallowing difficulty, and cognitive or motor impairment.
Tardive dyskinesia can produce repetitive movements of the mouth, tongue, face, trunk, or limbs and may become irreversible. Risk rises with cumulative exposure and appears greatest in older adults, particularly older women, although it can occur after relatively brief treatment or at low doses. Consider an older adult who becomes sleepy and unsteady after Rexulti is increased. Sedation, impaired motor function, and a blood-pressure drop on standing can combine with poor vision or muscle weakness to produce a serious fall. new facial movements, rigidity, swallowing trouble, fever, or abrupt confusion warrant prompt medical assessment rather than being dismissed as progression of dementia.
How Clinicians Choose and Monitor Auvelity or Rexulti
Before either medication is started, the care team should define observable target symptoms. “Agitated” is too vague; “strikes caregivers during morning bathing four times per week” or “paces and shouts for two hours most evenings” can be tracked. The person should also be checked for pain, urinary retention, constipation, dehydration, infection, sleep loss, hunger, medication side effects, and sudden environmental changes. The National Institute on Aging notes that agitation often has an identifiable contributor, including pain, stress, inadequate sleep, constipation, noise, or medication interactions. National Institute on Aging guidance on agitation Monitoring differs by drug. Auvelity calls for blood-pressure assessment, review of seizure risks, screening for bipolar disorder, and a complete inventory of bupropion- and dextromethorphan-containing products.
Rexulti warrants baseline and follow-up attention to weight, glucose, lipids, standing blood pressure, falls, swallowing, alertness, and abnormal movements. Both require a medication-interaction review, but the relevant metabolic pathways and dose adjustments differ. There is also a practical dosing tradeoff. Auvelity for Alzheimer’s agitation starts at 30 mg dextromethorphan/105 mg bupropion once each morning, with increases based on tolerability and a usual maximum of 45 mg/105 mg twice daily, at least eight hours apart. Rexulti starts at 0.5 mg once daily, rises to 1 mg during the second week, and reaches a recommended target of 2 mg daily on day 15; it may later be increased to 3 mg. Kidney function, liver function, interacting drugs, and individual metabolism can require lower limits, so caregivers should follow the prescribed schedule rather than copying a standard titration.
Common Problems During Treatment and Reassessment
A reduction in aggression is not necessarily a successful outcome if the person becomes excessively sedated, cannot walk safely, stops eating, or loses meaningful interaction. Caregivers should record both benefits and harms: frequency of aggression, duration of pacing, sleep, appetite, falls, participation in care, and daytime alertness. A brief daily log can reveal that shouting decreased only because the person now sleeps through meals, a tradeoff that should trigger reassessment. Both drugs require time and scheduled dosing; neither is approved for as-needed use. Giving an extra dose during an acute outburst can exceed the prescription and increase toxicity without acting like a rapid tranquilizer.
When someone suddenly becomes far more agitated over hours or a day, delirium from infection, dehydration, medication changes, urinary retention, or another acute illness should be considered before the behavior is attributed to Alzheimer’s disease. Long-term treatment should not continue on autopilot. Rexulti’s label recommends the lowest effective dose and periodic reassessment because tardive dyskinesia risk rises with duration and cumulative exposure. Nursing homes must also document the indication, monitoring, non-drug interventions, and clinically appropriate attempts at gradual dose reduction or the reason a reduction is contraindicated. Abruptly stopping or independently changing either medication is unsafe; tapering and relapse monitoring should be planned with the prescriber.
Non-Drug Care Alongside Medication
Medication generally works best as one part of a person-centered plan. Reducing noise, keeping routines predictable, adjusting bathing methods, treating pain, providing daytime activity, protecting sleep, and approaching from the person’s visible side can lessen distress. If agitation reliably begins when three caregivers enter a small bathroom, switching to one familiar caregiver and a sponge bath may reduce aggression more effectively than increasing a dose.
The response during an episode matters as well. Arguing about an incorrect belief, crowding the person, or forcing a task can intensify fear. A calm voice, physical space, redirection, and a pause before trying again may protect everyone while preserving dignity. Immediate emergency help is appropriate when there is serious danger, a major injury, stroke symptoms, seizure activity, extreme fever with rigidity, or an abrupt change in consciousness.
Questions Families Should Bring to the Prescriber
Families should ask which behaviors the medication is intended to change, why Auvelity or Rexulti fits the person’s diagnosis and medical history, what benefit would justify continued exposure, and which adverse effects require an urgent call. They should provide a complete list of prescriptions, supplements, and nonprescription products. A nighttime cough medicine containing dextromethorphan, for example, is clinically relevant when Auvelity is being considered.
The care plan should name a review date and measurable stopping criteria. One practical plan might reassess falls, blood pressure, aggression frequency, sleep, eating, and alertness after each dose change, followed by a formal decision about continuation once an adequate trial has occurred. Families should also clarify who will monitor weight and metabolic laboratory results with Rexulti or blood pressure, sodium-related symptoms, seizure risks, and serotonergic interactions with Auvelity.
Frequently Asked Questions
Is Auvelity safer than Rexulti for an older adult with Alzheimer’s disease?
Auvelity avoids the antipsychotic class boxed warning about increased mortality in older adults with dementia-related psychosis, but it has substantial risks of its own, including seizures, hypertension, falls, serotonin syndrome, neuropsychiatric reactions, and drug interactions. Safety depends on the individual’s history and medication list.
Can either medicine be given only when agitation occurs?
No. Both FDA labels state that the drugs are not indicated for as-needed treatment of agitation associated with Alzheimer’s dementia. They use scheduled dosing and gradual titration.
Are these drugs approved for every form of dementia?
No. Their agitation indications specifically concern dementia due to Alzheimer’s disease. Use in Lewy body, vascular, frontotemporal, or other dementias requires a separate clinical assessment and may involve different risks.
Does Auvelity treat depression and agitation at the same dose?
The labeled titration schedules differ. Treatment for Alzheimer’s agitation begins with a lower-strength Auvelity tablet and increases more slowly than the labeled major-depression schedule.
What symptoms require urgent medical attention?
A seizure, stroke symptoms, fainting, severe injury, suicidal behavior, extreme fever with rigidity, rapidly worsening confusion, trouble swallowing or breathing, or signs of serotonin syndrome require urgent evaluation.
